Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819859 | 0.97 | SLC6A4 (0.36) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18602892 | 0.92 | — | — | |
| SCHEMBL22944898 | 0.81 | SLC6A4 (0.37) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL19779413 | 0.78 | SLC6A4 (0.38) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL10867170 | 0.78 | USP2 (0.33) | — | |
| SCHEMBL198218 | 0.78 | USP2 (0.33) | — | |
| SCHEMBL258121 | 0.78 | USP2 (0.33) | — | |
| SCHEMBL29291476 | 0.78 | USP2 (0.33) | — | |
| SCHEMBL29291475 | 0.78 | USP2 (0.33) | — | |
| SCHEMBL24258293 | 0.76 | SLC6A4 (0.37) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177856-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-06-17 | — | — | US | disclosed |
| WO-2021021979-A2 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177856-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | ATR, MRE11, PARP2 | SLC6A4 4813/4885SLC6A3 4863/4885SLC6A2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.